170 related articles for article (PubMed ID: 21695651)
1. Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies.
Giembycz MA; Newton R
Handb Exp Pharmacol; 2011; (204):415-46. PubMed ID: 21695651
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: a novel mechanism for the clinical efficacy of roflumilast in severe chronic obstructive pulmonary disease.
Moodley T; Wilson SM; Joshi T; Rider CF; Sharma P; Yan D; Newton R; Giembycz MA
Mol Pharmacol; 2013 Apr; 83(4):894-906. PubMed ID: 23389862
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase inhibitors in the treatment of inflammatory diseases.
Page CP; Spina D
Handb Exp Pharmacol; 2011; (204):391-414. PubMed ID: 21695650
[TBL] [Abstract][Full Text] [Related]
4. [Phosphodiesterase-4 inhibitors: roflumilast].
Izquierdo Alonso JL
Rev Clin Esp; 2011 Mar; 211 Suppl 2():22-30. PubMed ID: 21596170
[TBL] [Abstract][Full Text] [Related]
5. Selective PDE inhibitors as novel treatments for respiratory diseases.
Page CP; Spina D
Curr Opin Pharmacol; 2012 Jun; 12(3):275-86. PubMed ID: 22497841
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
7. Is PDE4 too difficult a drug target?
Higgs G
Curr Opin Investig Drugs; 2010 May; 11(5):495-8. PubMed ID: 20419594
[TBL] [Abstract][Full Text] [Related]
8. Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases.
Abbott-Banner KH; Page CP
Basic Clin Pharmacol Toxicol; 2014 May; 114(5):365-76. PubMed ID: 24517491
[TBL] [Abstract][Full Text] [Related]
9. Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors.
Giembycz MA
Curr Opin Pharmacol; 2005 Jun; 5(3):238-44. PubMed ID: 15907909
[TBL] [Abstract][Full Text] [Related]
10. Roflumilast for the treatment of chronic obstructive pulmonary disease.
Antoniu SA
Curr Opin Investig Drugs; 2006 May; 7(5):412-7. PubMed ID: 16729716
[TBL] [Abstract][Full Text] [Related]
11. PDE4: a novel target in the treatment of chronic obstructive pulmonary disease.
Michalski JM; Golden G; Ikari J; Rennard SI
Clin Pharmacol Ther; 2012 Jan; 91(1):134-42. PubMed ID: 22130119
[TBL] [Abstract][Full Text] [Related]
12. Are phosphodiesterase 4 inhibitors just more theophylline?
Boswell-Smith V; Cazzola M; Page CP
J Allergy Clin Immunol; 2006 Jun; 117(6):1237-43. PubMed ID: 16750981
[TBL] [Abstract][Full Text] [Related]
13. Roflumilast for severe COPD?
Drug Ther Bull; 2011 Apr; 49(4):45-8; quiz iii-iv. PubMed ID: 21467576
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology, clinical efficacy, and tolerability of phosphodiesterase-4 inhibitors: impact of human pharmacokinetics.
Tenor H; Hatzelmann A; Beume R; Lahu G; Zech K; Bethke TD
Handb Exp Pharmacol; 2011; (204):85-119. PubMed ID: 21695636
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological strategies for improving the efficacy and therapeutic ratio of glucocorticoids in inflammatory lung diseases.
Newton R; Leigh R; Giembycz MA
Pharmacol Ther; 2010 Feb; 125(2):286-327. PubMed ID: 19932713
[TBL] [Abstract][Full Text] [Related]
16. [Selective phosphodiesterase-4 (PDE-4) inhibitors in COPD].
Tatlicioğlu T
Tuberk Toraks; 2008; 56(4):472-84. PubMed ID: 19123088
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.
Dastidar SG; Rajagopal D; Ray A
Curr Opin Investig Drugs; 2007 May; 8(5):364-72. PubMed ID: 17520865
[TBL] [Abstract][Full Text] [Related]
18. Superiority of combined phosphodiesterase PDE3/PDE4 inhibition over PDE4 inhibition alone on glucocorticoid- and long-acting β2-adrenoceptor agonist-induced gene expression in human airway epithelial cells.
BinMahfouz H; Borthakur B; Yan D; George T; Giembycz MA; Newton R
Mol Pharmacol; 2015 Jan; 87(1):64-76. PubMed ID: 25324049
[TBL] [Abstract][Full Text] [Related]
19. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.
Karish SB; Gagnon JM
Ann Pharmacother; 2006 Jun; 40(6):1096-104. PubMed ID: 16735669
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase-4 inhibitor therapy for lung diseases.
Beghè B; Rabe KF; Fabbri LM
Am J Respir Crit Care Med; 2013 Aug; 188(3):271-8. PubMed ID: 23656508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
